Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,268 | $571 | $303 | $259 |
| - Cash | $225 | $58 | $60 | $77 |
| + Debt | $6 | $6 | $1 | $2 |
| Enterprise Value | $1,049 | $519 | $245 | $184 |
| Revenue | $0 | $0 | $0 | -$1 |
| % Growth | – | – | 100% | – |
| Gross Profit | -$20 | -$0 | $0 | -$1 |
| % Margin | – | – | – | 100% |
| EBITDA | -$34 | -$41 | -$38 | -$40 |
| % Margin | – | – | – | 6,089.3% |
| Net Income | -$34 | -$41 | -$36 | -$38 |
| % Margin | – | – | – | 5,646% |
| EPS Diluted | -0.37 | -0.46 | -0.42 | -0.55 |
| % Growth | 19.6% | -9.5% | 23.6% | – |
| Operating Cash Flow | -$30 | -$25 | -$40 | -$59 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$30 | -$25 | -$40 | -$59 |